Cardiovascular revascularization medicine : including molecular interventions
-
Cardiovasc Revasc Med · Jan 2010
Case ReportsClosure of a coexisting ostium secundum atrial septal defect and patent foramen ovale using a single Amplatzer patent foramen ovale occluder device.
We report the case of a 59-year-old man with cryptogenic stroke who was found to have both an ostium secundum atrial septal defect and a patent foramen ovale (PFO) by intracardiac echocardiography. Both defects were successfully occluded using a single 35-mm Amplatzer PFO occluder device inserted through the atrial septal defect.
-
Cardiovasc Revasc Med · Jan 2010
Predictors of myocardial contractile recovery after coronary revascularization in patients with prior myocardial infarction.
We sought to explore the prognostic power of certain patient characteristics to predict myocardial contractile recovery after coronary revascularization in patients with prior myocardial infarction. ⋯ In patients with prior myocardial infarction, the presence of Grade 2-3 collaterals to the infarct-related artery and the shorter age of infarction at the time of revascularization independently predicted myocardial contractile recovery after coronary revascularization.
-
Cardiovasc Revasc Med · Jul 2009
Comparative StudyHead-to-head comparison of bivalirudin versus heparin without glycoprotein IIb/IIIa inhibitors in patients with acute myocardial infarction undergoing primary angioplasty.
In patients receiving primary percutaneous coronary intervention for ST elevation myocardial infarction (STEMI), bivalirudin with provisional glycoprotein (GP) IIb/IIIa inhibitors has been demonstrated to be noninferior to heparin plus systematic GP IIb/IIIa inhibitors in preventing recurrent ischemic events with improved safety in terms of bleeding. However, no study has been performed comparing head-to-head bivalirudin with heparin without GP IIb/IIIa inhibitor infusion in STEMI patients. ⋯ This study suggests that bivalirudin and heparin present similar safety and efficacy profiles when used without GP IIb/IIIa inhibitor infusion during primary angioplasty.
-
Cardiovasc Revasc Med · Apr 2009
Case ReportsShut that door: a man with contemporaneous multisite paradoxical embolization.
Patent foramen ovale (PFO) has been recognized as mediator of paradoxical embolism. Concurrent multisite paradoxical embolization is a quite rarely reported occurrence. We present a case of multisite paradoxical embolism (pulmonary, cerebral, upper limb) mediated by a large right-to-left shunt mediated by a PFO with associated a redundant Eustachian valve, successfully treated with PFO transcatheter closure and vena cava filter placement.